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Introduction
A large body of studies has shown that endothelial growth
factors involved in neo-angiogenesis are largely responsi-
ble for or associated with tumor progression and spread.
The activation of endothelial cells during tumorigenesis
has been defined as the result of the locoregional imbal-
ance between pro-angiogenic and anti-angiogenic factors
[1].
Vascular endothelial growth factor (VEGF) and basic
fibroblast growth factor (bFGF) are two heparin-binding
molecules with potent angiogenic properties both in vivo
and in vitro. VEGF comprises four alternative splicing vari-
ants that exert a similar activity on endothelial cell prolifera-
tion, on in vitro migration and on in vivo permeability.
VEGF-soluble proteins bind to two specific tyrosine-kinase
receptors, VEGFR-1 (flt-1) and VEGFR-2 (flk-1/KDR),
bFGF = basic fibroblast growth factor; CV = coefficient of variation; ER = estrogen receptor; PBS = phosphate-buffered saline; PgR = proges-
terone receptor; ROC = receiver operating characteristic; VEGF = vascular endothelial growth factor.
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Abstract
Introduction The aim of the present study was to analyze the
relationship between the expression of vascular endothelial
growth factor (VEGF) and basic fibroblast growth factor
(bFGF) in breast cancer cells and the corresponding serum
levels in individual patients. The study also evaluated the
potential of serum levels of the two growth factors as
diagnostic markers in a case–control study.
Methods VEGF expression and bFGF expression were
determined in 62 and 63 tumor samples, respectively. Serum
VEGF and bFGF levels were determined in 54 and 65 healthy
women and in 69 and 73 breast cancer patients, respectively,
using a quantitative sandwich enzyme immunoassay technique.
Results A direct correlation was observed between VEGF
expression and bFGF expression in individual tumors
(P = 0.001) and between serum levels (P = 0.038) in
individual patients, but not between tumor cell expression
and the corresponding serum level for either growth factor.
Median values of serum levels in healthy women and breast
cancer patients were not different for VEGF (P = 0.055), but
were significantly different for bFGF (P < 0.001). The
receiver operating characteristic curve identified a serum
bFGF concentration of 1.0 pg/ml, with 84.9% sensitivity and
63.1% specificity, as the best cut-off value to discriminate
between healthy women and breast cancer patients. An age-
based subgroup analysis showed that serum values of
patients older than 70 years of age mainly contributed to the
high accuracy.
Conclusions Our data repropose bFGF as a noninvasive
diagnostic tool for breast cancer.
Keywords: breast cancer, diagnostic tool, growth factors, serum levels
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which are expressed preferentially in endothelial cells.
bFGF is the most widely investigated member of the
fibroblast growth factor family. In normal tissue bFGF is
present in basement membranes and in the subendothelial
extracellular matrix of blood vessels, and stays membrane-
bound as long as there is no signal peptide. In particular, it
has been hypothesized that, during both wound healing of
normal tissues and tumor development, the action of
heparan sulfate degrading enzymes activates bFGF, thus
mediating the formation of new blood vessels [2,3].
Higher VEGF and bFGF levels have been found in the
serum and urine of patients with different tumor types than
in healthy individuals [4–7], and in the serum of patients
with metastatic disease than in those with localized
disease [8,9]. Some studies in patients with breast cancer
have investigated the potential of serum VEGF and bFGF
levels for diagnostic purposes [5–7,9,10] or for monitor-
ing the clinical course of disease [11–14]. A decrease in
VEGF serum levels [5,8,15] and a tendency of VEGF to
increase after breast cancer surgery [16] have been
reported. These controversial results could perhaps be
ascribed to the lack of standardization of the pre-analytical
phase related to the serum separation time and the clot-
ting temperature, which can influence platelet activation
and, consequently, compromise reliability and repro-
ducibility of the determinations [15,17–19].
Very little information is available for bFGF with respect to
platelet activation [20,21]. There is some evidence of the
potential of its level in serum for disease monitoring
[11–13], and only one group has investigated its role in
the early detection of breast cancer [6].
In the present study, we analyzed the relationship between
the expression of VEGF and bFGF in breast cancer cells
and the corresponding serum levels in individual patients.
We also aimed to define the potential of serum levels of




The study was conducted on healthy women and on
patients with breast cancer. Most of the patients were
recruited from individuals attending the Screening
Program run by the Prevention Unit of the Medical Oncol-
ogy Department of Pierantoni Hospital, and all of the
women were older than 50 years of age (range,
51–92 years; median, 67 years). All patients had histologi-
cally confirmed breast cancer.
The control group comprised women who were free from
any disease associated with an increased angiogenic
activity such as diabetic retinopathy, heart disease or lung
disease, which could affect VEGF levels and, possibly,
bFGF levels. Healthy women ranged in age from 51 to
77 years, with a median age of 60 years.
The study was examined and approved by the Ethics
Committee of the Local Health and Social Services
(Azienda USL, Forlì) in accordance with the ethical stan-
dards laid down in the 1964 Declaration of Helsinki.
Written informed consent was obtained from all the
women participating in the study.
Growth factors were determined in the tumor and in the
serum. Specifically, VEGF and bFGF expression was
determined in 62 and 63 tumor samples, respectively.
Serum VEGF and bFGF levels were determined in 54 and
65 healthy women, and in 69 and 73 breast cancer
patients, respectively.
Immunohistochemical determinations
Tumor tissue removed during surgery was fixed in neutral
buffered 10% formalin and embedded in paraffin. Four-
micrometer sections of the histologically confirmed tumor
samples were mounted on positive-charged slides
(BioOptica, Milan, Italy), deparaffinized with xylene, re-
hydrated, and the endogenous peroxidase activity blocked
by 3% hydrogen peroxide solution.
VEGF expression was determined using a polyclonal anti-
body that specifically reacts with isoforms 121, 165, 189,
and 206 (Biogenex, San Ramon, CA, USA). bFGF expres-
sion was determined using a monoclonal antibody that
reacts with the bFGF 18–24 kDa isoforms (Transduction
Laboratories, Lexington, KY, USA). Expression of the
estrogen receptor (ER) and of the progesterone receptor
(PgR) was determined using 1D5 and 1A6 monoclonal
antibodies, respectively (Biogenex).
VEGF, bFGF, ER, and PgR antigen retrieval was per-
formed by microwaving at 75 W for 15 min in 10 mM
citrate buffer (pH 6.0) followed by cooling at room temper-
ature for at least 20 min. The sections were then treated
for non-specific binding with 3% bovine serum albumin in
PBS for 20 min, after which they were incubated for
1 hour at room temperature with prediluted polyclonal anti-
VEGF antibody or monoclonal anti-ER and anti-PgR anti-
bodies or anti-bFGF monoclonal antibody diluted 1:100 in
PBS. Positive control slides (HL-60, K562, and HeLa
tumor cell lines for VEGF and bFGF, and normal breast
tissue for ER and PgR) were stained in parallel with the
antibodies. The sections were washed with PBS, incu-
bated with universal biotinylated secondary antibody,
rinsed in PBS, and incubated with streptavidin–peroxidase
conjugate (LSAB+kit; DAKO Corporation, Carpinteria,
CA, USA) for 15 min. Sections were rinsed again in PBS,
and antibody binding was detected by staining with
diaminobenzidine/hydrogen peroxidase chromogen solu-
tion (DAB+liquid substrate–chromogen solution; DAKOBreast Cancer Research    Vol 6 No 1 Granato et al.
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Corporation). Finally, sections were rinsed in deionized
water, were counterstained blue by Mayer’s Hemalum,
and were mounted in Eukitt (Bio-Optica).
VEGF and bFGF expression was evaluated at a light
microscope (200 ×) by two independent observers (AMG
and LM). Immunoreactivity was expressed as the percent-
age of the immunopositive area in relation to the total area
of invasive neoplastic tissue of the whole section. ER and
PgR analysis was performed by an image analyzer system
(CAS 200; Becton Dickinson, San Jose, CA, USA) and
expressed as already described.
Immunoassay
Peripheral venous blood was collected in sterile test tubes
(Vacutainer System; Becton Dickinson), left to coagulate
at 4°C for 30 min, centrifuged at 2000 × g for 10 min, and
then stored in aliquots at –70°C for a maximum of
1 month.
VEGF and bFGF levels were determined using a quantita-
tive sandwich enzyme immunoassay technique (Quan-
tikine; R&D System, Minneapolis, MN, USA) and all
samples were tested in duplicate. Briefly, 100 µl assay
diluent and 100 or 150 µl serum sample for VEGF and
bFGF, respectively, or scalar concentrations of VEGF
(15.6, 31.2, 62.5, 125, 250, 500, 1000 and 2000 pg/ml)
and bFGF (0.5, 1, 2, 4, 8, 16, 32 and 64 pg/ml) were
added to each well of a microtiter plate precoated with
mouse antihuman VEGF or mouse antihuman bFGF
monoclonal antibody. Plates were incubated at room tem-
perature for 2 or 3 hours for VEGF and bFGF, respec-
tively. The wells were then washed to remove unbound
VEGF or bFGF, supplemented with 200 µl enzyme-linked
anti-VEGF or anti-bFGF polyclonal antibodies and incu-
bated for 2 hours at room temperature. The wells were
washed again, supplemented with antibody-linked enzyme
substrates, and left for 25 min at room temperature. For
bFGF assay only, an amplifier solution was added and the
reaction was prolonged for 25 min.
After the addition of 50 µl stop reagent (2 M sulphuric
acid), the color intensity in each well was measured at
450 nm for VEGF and at 490 nm for bFGF using a spec-
trophotometer (Medical System, Genoa, Italy). The optical
density found in the serum samples was compared with a
standard curve of VEGF and bFGF concentrations and
was quantified. The coefficient of linearity, which shows
the linear correlation between measured absorbance and
known amounts of standards, was at least 0.9 for both
bFGF and VEGF. The minimum detectable concentration
ranged from 0.05 to 0.56 pg/ml for bFGF and was less
than 9 pg/ml for VEGF, as quoted by the manufacturer.
With regard to intra-assay reproducibility, the determina-
tions of growth factor serum levels were performed in
duplicate and were repeated when the coefficient of varia-
tion (CV) exceeded 15%. The highest disagreement
between the pair values was observed for low levels of the
growth factors. Overall, the CV was less than 15% in 85%
of cases for either VEGF (105 out of 123 samples) or
bFGF (117 out of 138 samples). The CV was less than
10% in 76% of cases for VEGF and in 68% of cases for
bFGF.
Assessment of interassay reproducibility was made by cal-
culating the CV for growth factor levels of serum samples
from five individuals run in quintuplicate. The CV for VEGF
determinations ranged from 4.9% to 9.5%, and that for
bFGF from 3% to 13.3%. In consideration of the low
serum concentrations of bFGF and of the fact that the
tests were carried out manually, we considered a CV
higher than 10% but lower than 15% acceptable.
Statistical analysis
Nonparametric ranking statistics (median test) were used
to analyze the relationship between the percentage of
positive tumor cells and the serum levels of VEGF and
bFGF, considered as continuous variables, and patient
characteristics. Spearman’s correlation coefficient was
used to investigate the relationship between the two
markers in the serum or in the tumor. The relation between
VEGF and bFGF serum levels and the presence of breast
cancer in the case–control study was analyzed using the
median test.
The most accurate cut-off value capable of discriminating
between healthy women and cancer patients, in the
absence of internationally accepted cut-off values for
serum bFGF and VEGF concentrations, was identified
using a receiver operating characteristic (ROC) curve
analysis. In the ROC curve the true positive rates (sensitiv-
ity) were plotted against the false positive rates (speci-
ficity) for all classification points. Ninety-five percent




Vascular endothelial growth factor
The percentage of the tumor immunopositive areas ranged
from 5 to 100% (median, 65%) and the immunoreaction
was limited to the cytoplasm. Tumor immunopositivity was
not related to patient age, to tumor size, or to lymph node
involvement. Tumor immunopositivity was significantly
higher in ductal tumor than in other histologies and, unex-
pectedly, higher in ER-positive and grade 1–2 tumors than
in ER-negative or grade 3 tumors (Table 1).
Serum levels ranged from 22.7 to 953.5 pg/ml (median,
192.7 pg/ml) and were not related to any biological or
pathological variable.Basic fibroblast growth factor
The percentage of the immunopositive areas varied greatly
in the different tumors, from a total absence to positivity
over the whole tumor area. In the majority of cases (84%)
positivity was limited to the cytoplasm, and in a minority
(16%) it was observed in both the nucleus and the cyto-
plasm of the tumor cells. Moreover, in the contiguous
macroscopically normal mammary epithelium, positivity
was limited to the cell nuclei of the basal layer of mammary
ducts. bFGF tumor expression was similar in the sub-
groups defined by different clinical, pathological, and hor-
monal characteristics (Table 2).
Serum levels ranged from 0.3 to 26.6 pg/ml (median,
2.3 pg/ml) and once again values were not statistically dif-
ferent as a function of different pathological and biological
variables.
A linear correlation was observed between VEGF and
bFGF expression in individual tumors (P = 0.001) and
between serum levels (P = 0.038) in individual patients
(Table 3). No correlation was observed between tumor
cell expression and the corresponding serum level for
either growth factor.
Case–control study
VEGF serum levels in healthy women ranged from 0 to
707.6 pg/ml, with a median value of 145.7 pg/ml. bFGF
serum levels in healthy women varied from 0 to 5.7 pg/ml,
with a median value of 0.4 pg/ml.
A considerable overlapping of serum VEGF levels
between healthy women and breast cancer patients was
observed, and median values were not significantly differ-




Tumor and serum vascular endothelial growth factor (VEGF) in relation to clinical, pathological and biological characteristics in
breast cancer patients
Tumor VEGF Serum VEGF
Number  % positive cells  Number  Serum level (pg/ml) 
of cases [median (range)] P of cases [median (range)] P
Age
51–70 years 40 65 (10–100) 43 180.5 (30.8–768.4)
0.91 0.11
> 70 years 22 65 (5–100) 26 241.5 (22.7–953.5)
Histotype
Ductal 53 70 (5–100) 56 189.9 (30.8–953.5)
0.02 0.71
Others 9 50 (10–75) 13 238.4 (22.7–456.8)
Tumor size
≤ 2 cm 42 70 (10–100) 49 193.6 (30.8–953.5)
0.09 0.42
> 2 cm 20 47.5 (5–90) 19 144.5 (22.7–561.0)
Node status
Node-negative 30 70 (15–95) 34 204.4 (36.6–768.4)
0.22 0.50
Node-positive 27 60 (5–100) 25 144.5 (22.7–953.5)
Grade
1–2 38 75 (10–100) 40 183.7 (30.8–768.4)
0.05 0.348
3 11 35 (5–90) 11 144.5 (36.3–953.5)
Steroid status
ER-positive 43 70 (10–95) 47 187.0 (30.8–953.5)
0.05 0.45
ER-negative 10 30 (5–90) 10 270.8 (48.3–768.4)
PgR-positive 31 65 (10–95) 34 187.1 (30.8–953.5)
0.72 0.70
PgR-negative 22 67.5 (5–95) 23 193.6 (48.3–674.1)
ER, estrogen receptor; PgR, progesterone receptor.highest value (707.6 pg/ml) detected in healthy women in
only two (2.8%) cases (Fig. 1a).
A partial overlapping of bFGF serum levels in healthy
women and in breast cancer patients was also observed,
but the difference between the median values of the two
subgroups was significantly different (P < 0.001) (Fig. 1b).
Moreover, all values equal to or higher than 6.0 pg/ml
(8/8) referred to cancer patients, while the total absence
of bFGF in the serum (27/27) was only observed in
healthy women.
The ROC curve did not highlight any acceptable concen-
tration of serum VEGF in terms of either sensitivity or
specificity (Fig. 2a). Conversely, when calculated using
serum bFGF values of healthy women and of breast
cancer patients (Fig. 2b), the ROC curve identified a con-
centration of 1.0 pg/ml, with an 84.9% sensitivity and a
63.1% specificity, as the best discriminant (Table 4). For
patients older than 70 years of age, a similar sensitivity
(77.8%) and a higher specificity (78.6%) were observed.
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Table 2
Tumor and serum basic fibroblast growth factor (bFGF) in relation to clinical, pathological and biological characteristics in breast
cancer patients
Tumor bFGF Serum bFGF
Number  % positive cells  Number  Serum level (pg/ml) 
of cases [median (range)] P of cases [median (range)] P
Age
51–70 years 41 45 (0–90) 46 2.2 (0.3–15.1)
0.25 0.40
> 70 years 22 65 (5–100) 27 3.0 (0.4–26.6)
Histotype
Ductal 54 55 (0–100) 60 2.2 (0.3–26.6)
0.68 0.90
Others 9 60 (0–85) 13 2.3 (0.4–5.2)
Tumor size
≤ 2 cm 43 55 (5–100) 51 2.3 (0.3–26.6)
0.53 0.37
> 2 cm 20 63 (5–100) 21 1.9 (0.4–11.1)
Node status
Node-negative 30 63 (0–100) 35 2.5 (0.3–15.1)
0.69 0.43
Node-positive 27 65 (0–100) 28 2.0 (0.5–26.6)
Grade
1–2 38 62.5 (0–100) 42 2.3 (0.3–15.1)
0.99 0.57
3 12 60 (5–100) 13 3.1 (1.5–26.6)
Steroid status
ER-positive 43 45 (0–100) 49 2.2 (0.3–15.1)
0.43 0.32
ER-negative 10 65 (5–95) 11 3.5 (1.8–11.1)
PgR-positive 32 38 (0–100) 35 2.0 (0.4–8.6)
0.12 0.19
PgR-negative 21 70 (5–95) 25 2.5 (0.3–15.1)
ER, estrogen receptor; PgR, progesterone receptor.
Table 3
Correlation between serum and tumor vascular endothelial
growth factor (VEGF) and basic fibroblast growth factor
(bFGF)
rs P
Tumor VEGF versus tumor bFGF 0.420 0.001
Serum VEGF versus serum bFGF 0.200 0.038
Serum VEGF versus tumor VEGF 0.133 0.320
Serum bFGF versus tumor bFGF 0.037 0.775
rs, Spearman’s correlation coefficient.Discussion
Information on the clinical relevance of VEGF expression
and bFGF expression in breast cancer patients is incon-
clusive. In addition to positive data [22–24] negative
results on the prognostic relevance have been reported
[25], particularly when their role was assessed according
to internationally accepted guidelines in a large series of




Basic fibroblast growth factor sensitivity and specificity in women older than 50 years of age*
Number of cases/controls Sensitivity (%) Specificity (%)
Overall series 73/65 84.9 (95% CI, 76.7–93.1) 63.1 (95% CI, 51.4–74.8)
51–70 years old 46/51 76.1 (95% CI, 63.8–88.4) 64.7 (95% CI, 51.6–77.8)
> 70 years old 27/14 77.8 (95% CI, 62.1–93.5) 78.6 (95% CI, 57.1–100.0)
CI, confidence interval. * Cut-off value, 1.00 pg/ml.
Figure 1
Box plots of (a) vascular endothelial growth factor (VEGF) and (b) basic fibroblast growth factor (bFGF) serum levels. The lower boundary of the
box is the 25th percentile and the upper boundary is the 75th percentile. The bold line inside the box represents the median. * Cases with values
more than 1.5 box lengths from the upper or lower edge of the box (extreme values). The largest and smallest observed values that are not extreme
values are also shown (whiskers).
Figure 2
Receiver operating characteristic curve of (a) vascular endothelial growth factor and (b) basic fibroblast growth factor serum levels. CI, confidence
interval.type of systemic therapy [26]. To exert their potent angio-
genic effect, however, these growth factors have to be
secreted by tumor cells, and altered amounts are therefore
expected to be present in the blood of patients.
In the present study, we found a correlation in individual
patients between the expression of VEGF and bFGF in
tumor cells as well as between their levels in serum, but
not between the expression in tumor cells and the serum
concentration of either growth factor. It is also worthy of
note that bFGF expression in tumor cells was not corre-
lated with any conventional pathological or biological vari-
able of prognostic relevance and that VEGF expression
was not significantly related to tumor size or to nodal
involvement. Furthermore, VEGF expression was signifi-
cantly higher in ductal tumors and, paradoxically, inversely
related to the grade and the ER level, as already observed
by other authors [15]. It can therefore be concluded that
the expression of these growth factors is not closely
related to tumor growth and progression, which could
justify the negative results on their prognostic relevance.
The question now arises: what point in the preclinical or
the clinical tumor lifespan do cancer cells produce angio-
genic factors, and when do these become determinant in
stimulating and supporting tumor growth? Preliminary but
suggestive data have shown that VEGF serum levels of
patients with in situ breast carcinoma are comparable
with, if not higher than, those detected in the sera of
women with primary invasive breast cancer [7,9]. This
finding was also observed for serum levels of bFGF in a
small preliminary series of patients with in situ carcinoma
(data not shown). This suggests that the secretion of
angiogenic factors might occur in the early phases and
might play an important role in preclinical tumor life [27].
To verify the potential of VEGF and bFGF serum levels as
noninvasive diagnostic markers, we performed a case–
control study. Our results seem to indicate that VEGF
serum levels are not useful as a diagnostic tool for breast
cancer due to the considerable overlapping of the sets of
values observed in healthy women and in patients, in
agreement with some previous results [28,29] and in con-
trast with others [7,9]. We would like to underline,
however, that our data were obtained under strict stan-
dardized conditions for the serum separation time and the
clotting temperature, both important pre-analytical
aspects, since VEGF levels in the serum are known to be
largely platelet derived [17–19,30–33]. Our evidence is
supported by the negative results on the clinical relevance
of VEGF detected in nipple aspirate fluid [27], indepen-
dent of any platelet activation.
Positive results were conversely observed for bFGF serum
levels that, although partially overlapping in healthy women
and in patients, showed statistically different median
values in the two groups. Moreover, a total absence of
bFGF in serum was observed exclusively in healthy
women, while values equal to or higher than 6 pg/ml were
found only in breast cancer patients.
The ROC analysis identified a cut-off serum concentration
with a high sensitivity and a good specificity to identify
breast cancer patients. An age-based subgroup analysis
showed that serum values of patients older than 70 years
of age contributed largely to this sensitivity and specificity.
Our results are in agreement with those reported by other
authors who brought to light the importance of bFGF
serum levels in discriminating between healthy women
and breast cancer patients. These studies were con-
ducted using a nonstandardized inhouse enzyme
immunoassay methodology [6] on a heterogeneous series
of patients [11] or on small case–control subgroups [30].
The results from the present study, which was conducted
on a large, prospectively planned case–control series, in
which all the patients had operable tumors and in which all
determinations were carried out under strict standardized
and quality-controlled procedures, repropose the useful-
ness of the bFGF serum level for breast cancer detection.
The determination of serum bFGF represents a simple,
inexpensive and noninvasive approach, also when com-
pared with recently proposed nipple aspiration [27], and
would seem to be indicated mainly for women older than
70 years of age to whom mammograms and clinical
screening are not routinely offered. Moreover, bFGF would
seem to have a higher accuracy than other biomarkers
such as carcinoembryonic antigen or cancer antigen 15.3,
which were proposed for cancer diagnosis some years
ago and, albeit not fully validated [34], are now used for
monitoring purposes.
Conclusion
The bFGF serum level is associated with the presence of
breast cancer. Its usefulness for the early detection of
sporadic cancer, within screening programs, and in moni-
toring members of high-risk breast cancer families war-
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